Pharma and laboratory591467-2026

Portugal – Various medicinal products – VACINAS - VACINA CONTRA O PAPILOMAVIRUS HUMANO (NONAVALENTE)

Serviços de Saúde da Região Autónoma da Madeira, EPERAM (SESARAM; EPERAM)

Buyer country

Portugal

Publication date

Not specified

Biderra sector

Pharma and laboratory

Data source

TED open data

Decision signals

First-pass opportunity review

These signals are calculated from the indexed fields. They help prioritize a review but do not replace eligibility checks in the official procurement documents.

Timing signal
Deadline not indexed

Check the official notice

Indexed data completeness
86%

Based on seven decision fields

Official title coverage
7 languages

Preserved from source-supplied versions

Classification signal
33690000

Medical equipment, pharmaceuticals and personal care products

Official title versions

TED may publish the same notice title in several official languages. Biderra preserves the versions supplied in the source feed.

Spanish

Portugal – Medicamentos diversos – VACINAS - VACINA CONTRA O PAPILOMAVIRUS HUMANO (NONAVALENTE)

Dutch

Portugal – Diverse geneesmiddelen – VACINAS - VACINA CONTRA O PAPILOMAVIRUS HUMANO (NONAVALENTE)

Polish

Portugalia – Różne produkty lecznicze – VACINAS - VACINA CONTRA O PAPILOMAVIRUS HUMANO (NONAVALENTE)

French

Portugal – Médicaments divers – VACINAS - VACINA CONTRA O PAPILOMAVIRUS HUMANO (NONAVALENTE)

German

Portugal – Varia – VACINAS - VACINA CONTRA O PAPILOMAVIRUS HUMANO (NONAVALENTE)

Italian

Portogallo – Medicinali vari – VACINAS - VACINA CONTRA O PAPILOMAVIRUS HUMANO (NONAVALENTE)

English

Portugal – Various medicinal products – VACINAS - VACINA CONTRA O PAPILOMAVIRUS HUMANO (NONAVALENTE)

What Biderra adds

For notice 591467-2026, Biderra has normalized the contracting authority country as Portugal, grouped CPV 33690000 under pharma and laboratory, compared the available deadline fields with today, measured field completeness, and preserved 7 source-supplied title versions. The official record remains decisive.